Request Clinical Starter Kits for Your Patients Today! Request Now

Are you a clinician?

This is a clinician-only website.
By entering, you acknowledge that you're a clinician.

ENDUR-ACIN® helps inhibit progression of atherosclerosis, study shows

Highlights

  • ENDUR-ACIN® improves blood lipids in patients with CAD and primary hyperlipidemia
  • Effective dosage is 1,500 mg/day for 2 years
  • Most patients (75%) also achieved stabilization of atherosclerosis

Summary

The aim of this preliminary study was to examine the effect of ENDUR-ACIN® treatment on blood lipids and atherosclerotic progression in patients with coronary artery disease (CAD).

The study involved 13 patients, aged 39 to 60 years, with documented CAD and primary hyperlipidemia. The patients received ENDUR-ACIN® (1,500 mg/day) for up to 2 years.

ENDUR-ACIN® treatment resulted in a reduction in total cholesterol by 10.3% and low-density lipoprotein (LDL) cholesterol by 13.1% and an increase in high-density lipoprotein (HDL) cholesterol by 15.2%. In 75% of patients, stabilization of atherosclerosis was observed after 2 years of ENDUR-ACIN® treatment. Half of the patients experienced increased levels of liver transaminases, however discontinuation of treatment was not necessary.

These findings suggest that long-term use of ENDUR-ACIN® helps inhibit the progression of atherosclerosis in patients with CAD.

Reference

Kukharchuk VV, Solov’ev EIu, Malyshev PP, Rozhkova TA, Semenova OA, Aronskaia EE. The effect of long-term Enduracin monotherapy on the clinical and biochemical status of patients with ischemic heart disease (in Russian; English abstract). Ter Arkh. 1997;69(9):41-5.

PMID: 9411824